title: Adenosine monophosphate-activated protein kinase mediates the protective effects of ischemic preconditioning on hepatic ischemia-reperfusion injury in the rat.
abstract: Hepatic ischemia-reperfusion (I/R) injury associated with liver transplantation and hepatic resections are an unresolved problem in the clinical practice. Preconditioning is known to preserve energy metabolism in liver during sustained ischemia, but the molecular mechanisms underlying this effect are still unclear. Different metabolic signals, including adenosine monophosphate (AMP) and nitric oxide (NO), have been implicated in preconditioning. AMP-activated protein kinase (AMPK) protects cells by acting as a low-fuel warning system, becoming switched on by adenosine triphosphate (ATP) depletion. NO synthesis is induced by AMPK in the heart during ischemia. The aim of this study was to investigate: 1) whether preconditioning induces AMPK activation; and 2) if AMPK activation leads to ATP preservation and reduced lactate accumulation during prolonged ischemia and its relationship with NO. Preconditioning activated AMPK and concomitantly reduced ATP degradation, lactate accumulation, and hepatic injury. The administration of an AMPK activator, AICAR, before ischemia simulated the benefits of preconditioning on energy metabolism and hepatic injury. The inhibition of AMPK abolished the protective effects of preconditioning. The effect of AMPK on energy metabolism was independent of NO because the inhibition of NO synthesis in the preconditioned group and the administration of the NO donor before ischemia, or to the preconditioned group with previous inhibition of AMPK, had no effect on energy metabolism. Both preconditioning and AICAR pretreatment, through AMPK activation, may be useful surgical and pharmacologic strategies aimed at reducing hepatic I/R injury.
authors.affiliation: Depto Bioanalítica Médica, IIBB-CSIC, Barcelona, Spain.
authors.forename: C
authors.initials: C
authors.lastname: Peralta
authors.forename: R
authors.initials: R
authors.lastname: Bartrons
authors.forename: A
authors.initials: A
authors.lastname: Serafin
authors.forename: C
authors.initials: C
authors.lastname: Blázquez
authors.forename: M
authors.initials: M
authors.lastname: Guzmán
authors.forename: N
authors.initials: N
authors.lastname: Prats
authors.forename: C
authors.initials: C
authors.lastname: Xaus
authors.forename: B
authors.initials: B
authors.lastname: Cutillas
authors.forename: E
authors.initials: E
authors.lastname: Gelpí
authors.forename: J
authors.initials: J
authors.lastname: Roselló-Catafau
mesh_terms: D055372:AMP-Activated Protein Kinases; D000818:Animals; D004734:Energy Metabolism; D007511:Ischemia / Q000378:metabolism / Q000473:pathology*; D019194:Ischemic Preconditioning; D008099:Liver / Q000473:pathology; D008102:Liver Circulation; D008297:Male; D009097:Multienzyme Complexes / Q000502:physiology*; D017346:Protein Serine-Threonine Kinases / Q000502:physiology*; D051381:Rats; D017208:Rats, Wistar; D015427:Reperfusion Injury / Q000378:metabolism / Q000473:pathology*
chemical_list: D009097:Multienzyme Complexes; D017346:Protein Serine-Threonine Kinases; D055372:AMP-Activated Protein Kinases